Core Viewpoint - Recently, Tianjin Lifesun Pharmaceutical Co., Ltd. received a notification from the National Medical Products Administration regarding the approval of the supplementary application for Aminophylline Tablets, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1 - The approved specification for the drug is 0.1g, calculated based on C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O [1]

Core Viewpoint - Lisheng Pharmaceutical has received approval from the National Medical Products Administration for its 0.1g specification of Aminophylline tablets, which have passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Product Approval - The approval notification pertains to Aminophylline tablets, which are indicated for the relief of symptoms in bronchial asthma, asthmatic bronchitis, and obstructive pulmonary emphysema [1] - The drug is also applicable for asthma caused by cardiogenic pulmonary edema [1]

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

中新网济南1月29日电(周艺伟 赵晓)今年山东省两会期间，黄河流域生态保护和高质量发展再度成为山 东省政协委员关注的焦点。 如何将黄河流域治理的生态优势有效转化为发展动能？多位来自科研、政府和企业一线的山东省政协委 员，提出涵盖保育修复、盐碱地综合治理、产业赋能的系统路径，勾勒出山东探索黄河流域生态价值转 化机制的新图景。 "主动保育"筑牢生态价值转化根基 "过去一年，我走进东营、泰安、聊城等山东沿黄城市，开展生态环保宣讲、教育与学习交流活动，亲 身感受到山东生态保护的成果。"山东省政协委员、澳门山东社团总会执行会长何超欣表示，她对山东 黄河流域的监察保护和保育工作印象深刻，并在《联合国气候变化框架公约》第三十次缔约方大会 (COP30)上推介了山东黄河流域保育的实践经验。 生态价值转化的前提是生态系统健康稳定。山东省政协委员、山东黄河河务局水政与河湖处(水政监察 总队)副处长延若新介绍，该局通过水资源统一调度与管理，动态调整山东各地配水方案，实现黄河水 资源的高效配置利用。"黄河连续26年不断流，山东段重要控制断面生态流量全部达标，为高质量发展 提供了坚实的水资源支持。" 2025年11月25日，山东黄河三 ...

证券代码：002393 证券简称：力生制药 公告编号：2026-007 天津力生制药股份有限公司 关于药品氨茶碱片通过仿制药一致性评价的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概况 近日，天津力生制药股份有限公司（以下简称"本公司"）收到国家药品监督管理局 颁发的关于氨茶碱片（以下简称"该药品"）0.1g（按 C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O 计）规 格的《药品补充申请批准通知书》（批件号：2026B00421），该药品通过仿制药质量 和疗效一致性评价。 二、该药品的基本情况 规格：0.1g（按C₂H₈N₂(C₇H₈N₄O₂)₂·2H₂O计） 注册分类：化学药品 药品生产企业：天津力生制药股份有限公司 原药品批准文号：国药准字H12020118 申请内容：仿制药质量和疗效一致性评价 受理号：CYHB2550123 审批结论：通过仿制药质量和疗效一致性评价。 三、该药品的相关信息 氨茶碱片适应症： 药品名称：氨茶碱片 剂型：片剂 公司该药品通过仿制药质量和疗效一致性评价，有利于提升该药品市场竞争力。由 于医药产品的行业特点，各类产品 ...

力生制药公告称，公司收到国家药监局颁发的氨茶碱片0.1g规格的《药品补充申请批准通知书》，该药 品通过仿制药质量和疗效一致性评价。此药适用于缓解支气管哮喘等喘息症状，也可用于心源性肺水肿 引起的哮喘。公司表示，该药品通过评价有利于提升市场竞争力，但医药产品销售受市场环境等因素影 响，具有不确定性，提醒投资者注意风险。 ...

Core Viewpoint - The company emphasizes its commitment to fulfilling social responsibilities sustainably while providing quality pharmaceuticals and health services to more patients in alignment with national policies and local needs [1]. Group 1 - The company acknowledges its role as a listed entity in meeting social responsibilities [1]. - Future efforts will focus on integrating national policy directions with local actual needs [1]. - The aim is to ensure that quality medicines and professional health services benefit a larger patient base [1].

Market Overview - The A-share market exhibited a fluctuating and differentiated pattern last week, with major indices showing mixed performance and active rotation among hot sectors [1][7] - Institutions generally hold an optimistic outlook, believing the market is likely to trend upward [1][7] - As of January 25, over 950 companies have disclosed their 2025 earnings forecasts, with around 40% of these companies showing positive performance [1][7] Semiconductor Industry - The semiconductor industry, particularly companies related to artificial intelligence, data center construction, and domestic substitution, is expected to see strong earnings growth in 2025 [1][8] - Notable companies include: - Zhongwei Semiconductor expects revenue of approximately 1.122 billion yuan, a year-on-year increase of about 23%, and a net profit of 284 million yuan, up approximately 107% [8] - Juchip Technology anticipates revenue of 922 million yuan, a 41.44% increase, and a net profit of 204 million yuan, up 91.40% [2] - Baiwei Storage forecasts revenue between 10 billion to 12 billion yuan, a growth of 49.36% to 79.23%, and a net profit of 850 million to 1 billion yuan, a staggering increase of 427.19% to 520.22% [3][9] Pharmaceutical Industry - The pharmaceutical sector is experiencing a "polarized" performance, with over 60 companies disclosing earnings forecasts, about half of which are positive [1][9] - Key performers include: - Zhaoyan New Drug expects a net profit of approximately 233 million to 349 million yuan, a year-on-year increase of 214% to 371% [10] - Shanghai Yizhong anticipates a net profit of 6 million to 7 million yuan, a growth of 760.18% to 903.54% [10] - However, companies like Zhifei Biological are projected to incur significant losses, with an expected net loss of 10.7 billion to 13.7 billion yuan [10][5] Banking Sector - As of January 25, eight listed banks have released earnings reports, with all showing year-on-year growth in net profit [5][11] - Key statistics include: - China Merchants Bank's total assets surpassing 13 trillion yuan, and Industrial Bank exceeding 11 trillion yuan [11] - The highest net profit growth among these banks is from Hangzhou Bank at 12.05%, followed by Shanghai Pudong Development Bank at 10.52% [11] - The growth drivers for banks include improved cost of liabilities and rapid growth in intermediary business income, with Ningbo Bank's net income from fees and commissions increasing by 30.72% [12]

资料显示，天津市三鱼诊所有限公司成立于2026年1月26日，法定代表人为马刚，注册资本100万人民 币，公司位于天津市，诊所服务、中医诊所服务（须在中医主管部门备案后方可从事经营活动）、保健 食品（预包装）销售、食品销售（仅销售预包装食品）、第二类医疗器械销售、第一类医疗器械销售、 企业管理咨询、市场营销策划、健康咨询服务（不含诊疗服务）、中医养生保健服务（非医疗）、卫生 用品和一次性使用医疗用品销售、病人陪护服务、康复辅具适配服务、家政服务、养生保健服务（非医 疗）、会议及展览服务（出国办展须经相关部门审批）、互联网销售（除销售需要许可的商品）。（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动）许可项目：医疗服务、药品零售、第三类 医疗器械经营、药品类易制毒化学品销售、依托实体医院的互联网医院服务、药品互联网信息服务、医 疗器械互联网信息服务。（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项目 以相关部门批准文件或许可证件为准）。 天眼查工商信息显示，近日，天津力生制药股份有限公司出资100万元成立天津市三鱼诊所有限公司， 持股100%，所属行业为卫生。 来源：市场资讯 ...

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1.本次回购注销的限制性股票授予日为2022年12月27日，本次回购注销限制性股票数 量共计30,016股，占回购前公司总股本257,616,859股的0.0117%，回购价格为8.76元/股。 2.截至2026年1月27日，上述限制性股票已在中国证券登记结算有限责任公司深圳分公 司办理完回购注销相关手续。 证券代码：002393 证券简称：力生制药 公告编号：2026-006 天津力生制药股份有限公司 关于部分限制性股票回购注销完成暨股份变动的公告 4.2022年11月15日，公司于巨潮资讯网（www.cninfo.com.cn）上披露了《监事会关于 公司2022年限制性股票激励计划授予激励对象名单的公示情况说明及核查意见》（公告编 号：2022-074）。 5.2022年12月5日，公司召开2022年第五次临时股东大会，审议并通过了《关于公司 2022年限制性股票激励计划（草案）及其摘要的提案》《关于公司2022年限制性股票激励 1 计划实施考核管理办法的提案》以及《关于提请公司股东大会授权董事会 ...